Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment

Chen, Ruijie; Zhai, Yuanyuan; Sun, Lining; Wang, Zeqing; Xia, Xing; Yao, Qing; Kou, Longfa

doi:10.1016/j.ajps.2022.02.003

Cited by 33 publications

(9 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [107] Periplogenin IMQ-induced Ps mice& TPA-induced epidermal hyperplasia mouse model Transdermal delivery [108] Nano formulation Alantolactone IMQ-induced Ps mice Transdermal delivery CHALT shows limited toxicity and good anti-psoriatic activity. [105] Selenium IMQ-induced Ps mice Transdermal delivery The biological inertness of SeNPs makes it cause less adverse effects. [106] HBOT O 2 IMQ-induced Ps mice —— HBOT gains superior security.…”

Section: Psoriasis and Ros Accumulationmentioning

confidence: 99%

“…In the IMQ-induced Ps mice model, oral saikosaponin A [103] or topical application of 18β-glycyrrhetinic acid [104] , alantolactone-loaded chitosan/hyaluronic acid nanoparticles (CHALT) ( Fig. 5 I) [105] and selenium nanoparticles (SeNPs) ( Fig. 5 II) [106] all play a role in promoting HaCaT cell apoptosis and inhibiting epidermal hyperplasia.…”

Section: Psoriasis and Ros Accumulationmentioning

confidence: 99%

“…The experimental design and the macroscopic images of psoriatic mice backs after seven days of CHALT treatment (C). (Reproduced with permission from [105] , Copyright ©2022, Shenyang Pharmaceutical University). (II): Mechanism of SeNPs in the treatment of psoriasis (A).…”

Section: Psoriasis and Ros Accumulationmentioning

confidence: 99%

See 2 more Smart Citations

A double-edged sword: ROS related therapies in the treatment of psoriasis

Bian

et al. 2022

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Psoriasis and Ros Accumulationmentioning

confidence: 99%

Section: Psoriasis and Ros Accumulationmentioning

confidence: 99%

See 1 more Smart Citation

A double-edged sword: ROS related therapies in the treatment of psoriasis

Bian

et al. 2022

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…recently reported that polymeric NPs composed of alantolactone-modified chitosan and hyaluronic acid (CHALT) could effectively inhibit the proliferation of keratinocytes via ROS-mediated loss of mitochondrial membrane potential and apoptosis. In addition, CHALT could also weaken the inflammatory response triggered by IL-6 and JAK/STAT3 signaling pathway in keratinocytes, thereby inhibiting the progression of psoriasis ( 89 ).…”

Section: Nps-mediated Drug Delivery For Psoriasis Therapymentioning

confidence: 99%

Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a chronic papulosquamous skin disease with an autoimmune pathogenic traits and strong genetic predisposition. In the past few decades, with the rapid development of molecular biology and cell biology, the inherent pathogenesis of psoriasis has been gradually elucidated, in which cytokine inflammatory loops, cell signaling pathways, and epigenetic factors such as miRNAs have been demonstrated to play important roles in regulating the development and progression of psoriasis. More importantly, understanding the pathogenesis of psoriasis has promoted the development of effective treatment for psoriasis. In this review, we systemically summarized the molecular mechanisms regulating the development and progression psoriasis, introduced various therapeutics used for clinical psoriasis therapy, and highlighted the recent advances in nanoparticles (NPs)-mediated drug delivery for psoriasis treatment.

show abstract

“…It was well-known that nanodelivery systems could enhance the drug performance by increasing solubility, improving stability, and facilitating drug delivery efficiency, and this strategy has been used in the treatment of many diseases, including ulcerative colitis, [20][21][22] arthritis, [23][24][25] atherosclerosis, [26][27][28] cancers, [29][30][31] as well as psoriasis. [32][33][34] The prepared bilirubin/V9302 nanoparticles (BVn) here could maintain certain drug ratio and stability, enhance drug delivery efficiency, and reverse symptoms and histologic changes in an imiquimod (IMQ)induced psoriasis mouse model (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Glutamine‐Based Metabolism Normalization and Oxidative Stress Alleviation by Self‐Assembled Bilirubin/V9302 Nanoparticles for Psoriasis Treatment

Jiang

Huang

Cai

et al. 2023

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Psoriasis is an immune-mediated chronic inflammatory skin disorder characterized by epidermal hyperplasia and infiltration of inflammatory cells. Even though the pathogenesis remains unclear, T helper 17 (Th17) cells-mediated inflammation and keratinocyte-involved proliferation are considered to play key roles during the occurrence and the development of psoriasis. Therefore, suppressing the infiltration/function of Th17 and the abnormal hyperplasia of keratinocytes can be a rational strategy for ameliorating and treating psoriasis. In this study, a self-assembly nanoparticle (BVn) is developed with bilirubin (an endogenous antioxidant) and V9302 (a blocker of ASCT2, an amino acid transporter mediating glutamine influx for providing energy and activating mammalian target of rapamycin [mTOR] pathway) to intervene the local metabolism and alleviate oxidative stress for psoriasis treatment. BVn effectively suppresses inflammatory keratinocyte proliferation and scavenges excess reactive oxygen species (ROS). In the in vivo psoriasis mouse model, BVn shows increased permeation and delayed retention in the psoriatic lesion and reverses the psoriasis-related symptoms, evidenced by the normalized keratinocyte condition and decreased Th17 infiltration/activation. Mechanism study indicates that BVn not only cut off the energy supply but also suppressed cell proliferation or lymph cell expansion by deactivating mTOR pathway, besides alleviated oxidative stress. BVn-based glutamine metabolism modulation strategy offers a promising strategy for psoriasis therapy.

show abstract

Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment

Cited by 33 publications

References 56 publications

A double-edged sword: ROS related therapies in the treatment of psoriasis

A double-edged sword: ROS related therapies in the treatment of psoriasis

Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis

Glutamine‐Based Metabolism Normalization and Oxidative Stress Alleviation by Self‐Assembled Bilirubin/V9302 Nanoparticles for Psoriasis Treatment

Contact Info

Product

Resources

About